DermTech, Inc.

DermTech, Inc. (Nasdaq: DMTK) is a precision dermatology company focused on non-invasive genomic skin analysis, operating in the healthcare and molecular diagnostics sector. The company entered public markets through a SPAC combination that closed in 2019, with its shares subsequently trading on Nasdaq under the DMTK ticker. This 10-Q, filed February 13, 2018, represents a quarterly disclosure from DermTech's pre-merger reporting period, capturing the company's financials ahead of its blank-check transaction. DermTech's core platform applies genomic technology to skin sample analysis, targeting conditions including melanoma. The filing is currently active in the SpacDesk archive. Sign up at SpacDesk for the full filing history, SPAC transaction timeline, and real-time monitoring on DMTK.